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Background: Neoscytalidium species (formerly Scytalidium species) are black fungi that usually cause cutaneous
infections mimicking dermatophytes lesions. Very few publications have reported invasive or disseminated
infections.
Case presentation: In this paper, we report the clinical presentations, treatments and outcomes of five cases of
invasive Neoscytalidium infections with cutaneous involvement, including two cases with disseminated infection, in
five renal transplant recipients. To our knowledge, this is the first report of a series—albeit small—of renal
transplant patients in whom this infection was identified. All cases occurred in a single hospital in Paris, France,
between 2001 and 2011. Patients all originate from tropical area.
Conclusion: Treatments of Neoscytalidium infection varied greatly, underlining the lack of a recommendation for a
standardized treatment. All patients were cured after long-term antifungal therapy and/or surgical excision.
Interestingly, one patient with disseminated infection involving the left elbow, the right leg, the lungs and the nasal
septum was cured by medical therapy only without surgery. This may suggest that in contrast to others mycoses
(such as mucormycosis), an adequate medical treatment could be sufficient for treating Neoscytalidium. We also
point out the difficulties we had in diagnosing two patients with Kaposi’s sarcoma because of the similarity of the
lesions. Furthermore, our report underlines the need to check for this rare infection in immunocompromised kidney
transplant recipients originating from tropical areas.
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Neoscytalidium spp. (formerly Scytalidium) are ascomy-
cetous fungi counted among a large and heterogeneous
group of fungi that cause phaeohyphomycosis. One of
the particular characteristics of these fungi, known col-
lectively as dematiaceous fungi or black mold, is to pro-
duce dark melanized hyphae [1]. They are distributed
worldwide in tropical and subtropical regions and are
principally known as phytopathogens [1–4]. Thus, they
are mainly associated with plants and fruit trees, but can
also be isolated from soil [1, 5].* Correspondence: arnaud.fekkar@psl.aphp.fr
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sometimes traumatic, with colonized plants or vegetable
residues [1]. They usually cause superficial infections
such as onychomycosis or dermatomycosis and are con-
sidered as “dermatophytes-like” pathogens [1–6]. The
two species involved in human infections are Neoscytali-
dium dimidiatum and its albino variant Neoscytalidium
hyalinum, which does not produce melanin [1, 7]. N.
dimidiatum is the synanamorph of Nattrassia mangi-
ferae (formerly Hendersonula toruloidea) that was de-
scribed for the first time in Egypt in 1933 by Nattrass as
a phytopathogen [8]. The first cases in human infection
were described in 1970 and consisted of ungual and cu-
taneous lesions in patients originating from tropicalis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Garinet et al. BMC Infectious Diseases  (2015) 15:535 Page 2 of 7areas [9]. The first case of N. hyalinum was described a
few years later in patients with similar lesions [10].
On rare occasions, Neoscytalidium may be involved in
deeper cutaneous and subcutaneous infections, as well
as disseminated infections, especially in immunocom-
promised patients. In this setting, various clinical forms
have been described, including central nervous system
abscesses, endophthalmitis, sinusitis, osteomyelitis, my-
cetoma, subcutaneous lesions and disseminated infec-
tions [1, 11–21].
We report here the clinical presentations, treatments
and outcomes of five deep cutaneous infections due to
Neoscytalidium spp., two of which involved dissemin-
ation, that occurred in five renal transplant recipients in
our institution in Paris, France.
Materials and methods
Definition of the cases
Proven invasive fungal disease was as defined by the
EORTC/MSG Consensus Group [22]. An invasive case
was defined as the presence of fungal elements in a spe-
cimen obtained by biopsy or needle aspiration from a
normally sterile site. Dissemination was defined as the
involvement of two or more non-contiguous sites.
Culture
Cultures for all samples were performed on Sabouraud
agar without cycloheximide and supplemented with
chloramphenicol and gentamicin. Media were incubated
at 25 °C. As Neoscytalidium grows faster than dermato-
phytes, cultures were positive in 2 to 4 days. Identifica-
tion was performed with macro/microscopic observation
of the culture.
Onychomycosis cases
All skin and nail samples collected in our laboratory be-
tween January 1, 2010 and December 31, 2011 were
reviewed to identify the cultures that led to the macro/
microscopic identification of Neoscytalidium spp.
Case presentation (Table 1)
Case 1
The first patient was a 53-year-old male who originated
from French Guyana. He had received a kidney trans-
plant in December 2000 for nephroangiosclerosis. At ad-
mission (in February 2001), his medications included
mycophenolate mofetil 250 mg daily, tacrolimus 3 mg
twice daily and prednisone 20 mg daily as immunosup-
pressant therapy. He was diagnosed as having Kaposi’s
sarcoma with cutaneous, gastric and gut localizations.
During his hospital work-up, a subcutaneous nodule was
found on the right leg. A biopsy of the nodule demon-
strated inflammation with fungal elements identified via
mycological culture as Neoscytalidium spp. This sameagent was found concomitantly on a toenail sample.
Chest and abdomen CT scans for staging found no in-
ternal fungal localizations. The patient’s blood cultures
were negative. A systemic oral antifungal therapy with
itraconazole (400 mg twice daily) was initiated but 2
months later the leg lesion was still culture-positive. The
lesion was thus excised but the surgery proved incom-
plete and the lesion remained secondarily positive.
Thereafter, local treatments with amphotericin B-
impregnated paraffin gauze were added, but again, sam-
ples collected 4 months after surgery were still positive
for mycelium filaments and culture. The patient was
then lost to follow-up for one and a half years. He reap-
peared in March 2005. Unexpectedly, no active fungal
lesion was detected and he was therefore considered as
cured of his Neoscytalidium infection.
Case 2
The second patient was a 64-year-old female born in
Ivory Coast. She was admitted for infection as a compli-
cation of Kaposi’s sarcoma in September 2002. Her med-
ical history included polycystic renal disease that
required renal transplantation in 1991, followed by ex-
tensive cutaneous Kaposi’s sarcoma in 1996. At admis-
sion, her medications included cyclosporine 100 mg
daily and prednisolone 10 mg daily. During her
hospitalization, various mycological examinations were
positive: direct examination of left foot, right foot (sole
and nail), and right leg lesion samples showed mycelian
filaments identified as a N. hyalinum in culture. Mag-
netic resonance imaging of the left foot showed inflam-
matory and edematous remodeling of tissues, difficultly
distinguishable from tumor infiltrations, but no bone le-
sions were observed. Initially, the treatment included
both local and systemic terbinafine but an interaction
with cyclosporine led to a fast deterioration of renal
function. The systemic treatment was thus discontinued
in regard to the risk for renal function and the clinical
regression of the lesions. The local terbinafine treatment
however was continued. Evolution was favorable with
negative mycological cultures 4 months later.
Case 3
The third patient was a 52-year-old male originating
from Mauritania who had received an initial renal trans-
plant in 1991 for polycystic renal disease and underwent
a second renal transplantation in 2000. At admission, his
medications included mycophenolate mofetil (750 mg
twice daily), tacrolimus (3 mg daily) and prednisone
(10 mg daily). In November 2007, he came back to the
hospital for a post-traumatic lesion on the right leg. Dur-
ing the dermatological examination, an infiltrated, pig-
mented, and painless lesion measuring approximately
1.5 cm in diameter was found on the anterior face of the
Table 1 Characteristics of 5 kidney transplant recipients with invasive or disseminated Neoscytalidium infection
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N. dimidiatum. The lesion was resected successfully and
no relapse was observed.
Case 4
The fourth patient was a 59-year-old male originated
from Cameroon admitted to the hospital in October
2011 for the exploration of two cutaneous lesions. He
had undergone renal transplantation in 1992 for end
stage renal disease of undetermined origin. He was re-
ceiving a second renal graft in February 2011. At admis-
sion, his treatment consisted of tacrolimus (15 mg twice
daily), mycophenolate mofetil (500 mg twice daily) and
prednisone (7.5 mg daily). One lesion in the right preti-
bial region and one ulcerative lesion on the dorsal sur-
face of the fifth toe of the right foot measuring 1 × 2 cm
were discovered during the dermatological examination
(Fig. 1). These lesions had appeared 3 months earlier
and grown progressively. Cultures of the lesions revealed
N. dimidiatum. Histology of both lesions showed a
granulomatous inflammation reaching the dermis. The
diagnosis was thus a disseminated N. dimidiatum fungal
infection with cutaneous involvement. Interestingly, N.
dimidiatum had been previously identified on toenail
samples in 2006. The patient was treated with voricona-
zole, 200 mg twice daily. The lesions regressed and
remaining lesions were surgically excised and local treat-
ment with topical ketoconazole applications under gauze
was added. The lesions completely disappeared 3
months after the diagnosis and voriconazole was stopped
after 5 months. No relapse occurred.
Case 5
The fifth patient was a 49-year-old male from the Re-
public of Congo. He was admitted to the hospital in
May 2011 for multiple active cutaneous lesions. His
medical history included a renal transplantation in Feb-
ruary 2010 for a nephropathy of unknown origin. TheFig. 1 Lesion due to Neoscytalidium dimidiatum in a kidney
transplant recipientlesions consisted of large painless ulcerated tumors on
the left elbow, an infiltrated nodule on the back and an
ulceration on the right leg (Fig. 2). Direct examination of
samples from these lesions showed many fungal ele-
ments. Culturing led to the identification of N. dimidia-
tum at all sites. For that isolate, the macro/microscopic
examination result was confirmed by internal tran-
scribed spacer (ITS) sequencing using the following
primers ITS1 5′-TCCGTAGGTGAACCTGCGG-3′ and
ITS4 5′-TCCTCCGCTTATTGATATGC-3′. Moreover,
bronchoalveolar lavage and nasal septum biopsy cultures
were also positive, thus illustrating a disseminated form
of N. dimidiatum. Blood cultures remained negative.
Minimal inhibitory concentrations as determined by
Etest (bioMérieux, Marcy l’Etoile, France) were:
0.032 μg/μL for voriconazole, 0.5 μg/μL for posacona-
zole, 12 μg/μL for fluconazole, and 0.38 μg/μL for
amphotericin B. The minimal effective concentration
was 0.064 μg/μL for both caspofungin and micafungin.
Treatment with voriconazole was initiated and immuno-
suppression was reduced to a bitherapy with prednisol-
one and tacrolimus. Evolution was favorable with
complete regression of the lesions (Fig. 2) within
12 months. The patient was then lost to follow-up for a
year, but in the following year he was received for a
medical visit during which the disappearance of lesions
with residual scars and negative cultures were observed.
Neoscytalidium superficial infections
In our hospital, over 2 years (January 1, 2010 to Decem-
ber 31, 2011), 4 466 cutaneous or skin appendage (i.e.
nail, skin or hair samples) were obtained from 2 577 pa-
tients for fungal confirmation/identification, resulting in
1 540 (977 patients) positive cultures. Among these lat-
ter, Neoscytalidium spp. were identified in 77 isolates
(5 % of all positive samples) from 42 patients represent-
ing 4.3 % of all patients with positive fungal culture. Pre-
cisely, 73.8 % of these Neoscytalidium patients (n = 31)
had N. dimidiatum and 26.2 % (n = 11) N. hyalinum.
Discussion
In endemic regions, Neoscytalidium spp. are an import-
ant cause of onychomycosis, accounting for 9 % of cases
in Nigeria, 24 % in Gabon, and up to 56 % in the West
Indies [23]. A retrospective study on cases occurring be-
tween 1994 and 1999 in mainland France showed that
Neoscytalidium spp. infections accounted for 3.6 % of
onychomycosis cases [3]. Similar results have been found
in the United Kingdom where Neoscytalidium spp. were
responsible for 3 % of onychomycosis cases [24]. These
cases are imported, involving migrants from endemic re-
gions [3]. The epidemiological data concerning Neoscy-
talidium superficial infection obtained in our hospital
over a 2-year analysis period (January 1, 2010 to
Fig. 2 Disseminated Neoscytalidium dimidiatum infection in a kidney transplant recipient. Lesion on the left elbow at presentation (2a) and after
2 months of voriconazole therapy (2b). Other localizations included the lungs, sinuses and right leg (2c and 2e). Microscopic examination of the arm
lesion showing hyphal fungal elements (2d). Photo of the 72-h culture from the arm lesion showing mold with a black center and white edges
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ous epidemiological studies performed in Paris and
London [25, 26] with respectively 67 and 73 % of cases
of neoscytalidiosis due to Neoscytalidium dimidiatum.
Only a few cases of invasive/disseminated Neoscytali-
dium infections have been described. An aspect of inter-
est for our case reports, although we only have five, is
that they all occurred in renal transplant patients. In an
article describing one case of invasive N. dimidiatum in-
fection in an immunocompetent adult and reviewing 10
others cases of invasive Neoscytalidium infections with
affection of deep organs, Elinav et al. reported that most
of their invasive Neoscytalidium infections occurred in
immunocompromised patients, including lung, renal or
cardiac transplant recipients [11]. Additional aspects re-
trievable from the literature include other underlying
conditions such as trauma, diabetes and cirrhosis. Neos-
cytalidium infections can occur in immunocompetent
patients, with at least two cases reported. Neoscytali-
dium infections have been reported to manifest as cen-
tral nervous system abscess, endophthalmitis, empyema,
sinusitis and spondylodiscitis. Some authors have re-
ported a poor prognosis with 50 % mortality for these
infections but did not outline attributable mortality.
Interestingly, of the deaths reported in the literature,
two occurred in renal transplant patients [11–21, 27].
Deep localized subcutaneous infections (similar to what
we report) are more frequently described in the literature.
These lesions have been reported in immunocompromisedpatients using long-term corticosteroids [16, 28], in a car-
diac transplant recipient [29], in renal transplant recipients
[7, 30], in a discoid lupus erythematosus patient [31], in a
case of liver cirrhosis [32], in a granulocytopenic child [21]
and in a T-cell deficient patient [33]. Most of them were
treated with a combination of systemic and local antifungal
agents. Skin is more generally a frequent site of phaeohy-
phomycosis, up to 26 % in one review [34].
All of our patients were from the Caribbean overseas
departments of France or from Africa and frequently
returned to their places of origin where Neoscytalidium
spp. are endemic [1]. Interestingly, one patient had a
concomitant onychomycosis due to Neoscytalidium (pa-
tient 1) and another had been diagnosed for onychomy-
cosis due to Neoscytalidium 5 years earlier (patient 4).
Patient 3 had similar lesions at an interval of 6 years.
Unfortunately, the fungus in the earlier lesion was not
identified (culture remained sterile), which reveals the
difficulties in diagnosing these infections. These observa-
tions suggest that patients with “dermatophyte-like”
superficial infections with mild or no symptoms are at
risk of developing a deep cutaneous infection after many
years of immunodepression. Therefore, in patients who
are particularly at risk, i.e. immunocompromised and
originated from tropical zones, checking and even sam-
pling for onychomycosis should be done.
We note that our cases occurred exclusively in renal
transplant recipients despite the fact that our institution
also performs heart, liver and hematopoietic stem cell
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for this observation but it is likely that the limited num-
ber of cases may play a role and moreover impair a rele-
vant statistical analysis. We note too that all our patients
were severely immunocompromised and had been re-
ceiving immunosuppressive drugs for a very long time.
Two had undergone renal transplantation twice. Fur-
thermore, opportunistic infections (i.e. Kaposi’s sarcoma,
Pneumocystis jiroveci pneumonia and toxoplasmosis)
were diagnosed in three of our patients, reflecting the
impairment of their immune function.
We encountered diagnostic difficulties in two patients
with Kaposi’s sarcoma. In one, it was difficult to deter-
mine if the concerned lesions were due to secondary in-
fection of Kaposi’s sarcoma lesions or primitive fungal
infections, especially on the patient’s black skin. A link
between Kaposi’s sarcoma and Scytalidium infection has
been reported in HIV-infected patients [35]. This might
suggest either that Kaposi’s lesions favor fungal infection
or that fungal lesions may be misidentified and necessi-
tate multiple biopsies and cultures for various infectious
analyses.
Neoscytalidium spp. infections have no standardized
treatment [1]. The mold is frequently resistant in vivo
despite in vitro susceptibility tests showing low minimal
inhibitory concentrations [MICs] [36–38]. In superficial
infections, oral and topical treatments classically used
against dermatophytes [griseofulvin, ketoconazole, itra-
conazole] are often ineffective with Neoscytalidium spp.,
possible due to melanin production [7, 36]. Successful
eradication of mycosis has been obtained with sys-
temic use of azoles [voriconazole and itraconazole] or
with amphotericin B. However, in most cases, healing
is protracted and combinations of drugs are often ne-
cessary [39].
In disseminated infections, many treatments have been
used with various outcomes. Elinav et al. reported that
four patients died and one was cured with amphotericin
B, three died and one was cured with voriconazole, one
died with posaconazole, and one was cured with ketoco-
nazole [11].
In our series, all patients were cured. The difficulties
in eradicating this infection and the absence of standard-
ized care are reflected in the variety of treatments used
for our patients. Importantly, patient five, who presented
a disseminated infection and large cutaneous lesions,
had a very good response under voriconazole only and
no need for surgical resection of the lesions. It should be
noted that the immunosuppressive regimen of this pa-
tient was downscaled, which might have enhanced his
cure. In the other cases, the combination of surgical ex-
cision and medical treatment of lesions appeared to be a
good option, as described in the literature, but we ob-
tained successful outcomes as well with only oralvoriconazole monotherapy in one patient and with only
surgical excision for another.
Conclusion
Deep cutaneous infections due to the black exotic mold
Neoscytalidium spp. are rare events occurring primarily
in immunocompromised patients such as the renal
transplant recipients described here. Dissemination can
occur and threaten prognosis. Systemic azole therapy
appears to be of interest and may prevent the need for
an immediate surgical intervention in some cases, al-
though for others, surgery remains the most appropriate
solution.
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